With a focus on diabetic retinopathy (DR) and age-related macular degeneration (AMD), we are developing novel oral therapies to address very large unmet needs and meet physicians’ requests for more effective treatments, earlier intervention and with less burden on patients to improve outcomes.
At Breye, our mission and vision are shaped by our responsibility to work towards sustainable, ethical, and forward-thinking practices. We integrate sustainability into all parts of our value chain.
Our Environmental, Social, and Governance (ESG) efforts are focused on two areas: the societal impact we can attain through our patients and products and the impact we can make through how we operate as a business.
As a member of the United Nations Global Compact, we are guided by its ten principles and the Sustainable Development Goals (SDGs), to make sure we are on the right path to reach a better and more sustainable future.
